title: Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".
authors: Pharmaceutical Technology Department, Faculty of Pharmacy, University of the Basque Country, P. Universidad, 7, 01006, Vitoria-Gasteiz, Spain, b.calvo@ehu.es.
authors: Begoña
authors: B
authors: Calvo
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000592:standards*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D060735:Pharmacovigilance
chemical_list: D059451:Biosimilar Pharmaceuticals